BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 23688559)

  • 1. Development of time resolved fluorescence resonance energy transfer-based assay for FXR antagonist discovery.
    Yu DD; Lin W; Chen T; Forman BM
    Bioorg Med Chem; 2013 Jul; 21(14):4266-78. PubMed ID: 23688559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Substituted isoxazole analogs of farnesoid X receptor (FXR) agonist GW4064.
    Bass JY; Caldwell RD; Caravella JA; Chen L; Creech KL; Deaton DN; Madauss KP; Marr HB; McFadyen RB; Miller AB; Parks DJ; Todd D; Williams SP; Wisely GB
    Bioorg Med Chem Lett; 2009 Jun; 19(11):2969-73. PubMed ID: 19410460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel heterocyclic scaffolds of GW4064 as farnesoid X receptor agonists.
    Smalley TL; Boggs S; Caravella JA; Chen L; Creech KL; Deaton DN; Kaldor I; Parks DJ
    Bioorg Med Chem Lett; 2015 Jan; 25(2):280-4. PubMed ID: 25499883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fragmentation of GW4064 led to a highly potent partial farnesoid X receptor agonist with improved drug-like properties.
    Flesch D; Gabler M; Lill A; Gomez RC; Steri R; Schneider G; Stark H; Schubert-Zsilavecz M; Merk D
    Bioorg Med Chem; 2015 Jul; 23(13):3490-8. PubMed ID: 25934227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, Synthesis, and Biological Evaluation of Novel Nonsteroidal Farnesoid X Receptor (FXR) Antagonists: Molecular Basis of FXR Antagonism.
    Huang H; Si P; Wang L; Xu Y; Xu X; Zhu J; Jiang H; Li W; Chen L; Li J
    ChemMedChem; 2015 Jul; 10(7):1184-99. PubMed ID: 25982493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transactivation and Coactivator Recruitment Assays for Measuring Farnesoid X Receptor Activity.
    Hsu CW; Zhao J; Xia M
    Methods Mol Biol; 2016; 1473():43-53. PubMed ID: 27518622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of FDA-approved drugs targeting the Farnesoid X Receptor.
    van de Wiel SMW; Bijsmans ITGW; van Mil SWC; van de Graaf SFJ
    Sci Rep; 2019 Feb; 9(1):2193. PubMed ID: 30778102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of trisubstituted-pyrazol carboxamide analogs as novel and potent antagonists of farnesoid X receptor.
    Yu DD; Lin W; Forman BM; Chen T
    Bioorg Med Chem; 2014 Jun; 22(11):2919-38. PubMed ID: 24775917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Progress in the ligands and their complex structures of farnesoid X receptor].
    Li WH; Fu J; Zheng MY; Liu GX; Tang Y
    Yao Xue Xue Bao; 2012 Jun; 47(6):704-15. PubMed ID: 22919716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-guided modification of isoxazole-type FXR agonists: Identification of a potent and orally bioavailable FXR modulator.
    Luo G; Lin X; Li Z; Xiao M; Li X; Zhang D; Xiang H
    Eur J Med Chem; 2021 Jan; 209():112910. PubMed ID: 33049605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel substituted isoxazole FXR agonists with cyclopropyl, hydroxycyclobutyl and hydroxyazetidinyl linkers: Understanding and improving key determinants of pharmacological properties.
    Kinzel O; Steeneck C; Schlüter T; Schulz A; Gege C; Hahn U; Hambruch E; Hornberger M; Spalwisz A; Frick K; Perović-Ottstadt S; Deuschle U; Burnet M; Kremoser C
    Bioorg Med Chem Lett; 2016 Aug; 26(15):3746-53. PubMed ID: 27268696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of an N-oxide pyridine GW4064 analog as a potent FXR agonist.
    Feng S; Yang M; Zhang Z; Wang Z; Hong D; Richter H; Benson GM; Bleicher K; Grether U; Martin RE; Plancher JM; Kuhn B; Rudolph MG; Chen L
    Bioorg Med Chem Lett; 2009 May; 19(9):2595-8. PubMed ID: 19328688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bile acid receptor agonist GW4064 regulates PPARγ coactivator-1α expression through estrogen receptor-related receptor α.
    Dwivedi SK; Singh N; Kumari R; Mishra JS; Tripathi S; Banerjee P; Shah P; Kukshal V; Tyagi AM; Gaikwad AN; Chaturvedi RK; Mishra DP; Trivedi AK; Sanyal S; Chattopadhyay N; Ramachandran R; Siddiqi MI; Bandyopadhyay A; Arora A; Lundåsen T; Anakk SP; Moore DD; Sanyal S
    Mol Endocrinol; 2011 Jun; 25(6):922-32. PubMed ID: 21493670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of new non-steroidal farnesoid X receptor modulators through 3D shape similarity search and structure-based virtual screening.
    Wang L; Si P; Sheng Y; Chen Y; Wan P; Shen X; Tang Y; Chen L; Li W
    Chem Biol Drug Des; 2015 Apr; 85(4):481-7. PubMed ID: 25228339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis of Novel Farnesoid X Receptor Agonists and Validation of Their Efficacy in Activating Differentiation of Mouse Bone Marrow-Derived Mesenchymal Stem Cells into Osteoblasts.
    Fujimori K; Iguchi Y; Yamashita Y; Gohda K; Teno N
    Molecules; 2019 Nov; 24(22):. PubMed ID: 31744088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unbinding pathways of GW4064 from human farnesoid X receptor as revealed by molecular dynamics simulations.
    Li W; Fu J; Cheng F; Zheng M; Zhang J; Liu G; Tang Y
    J Chem Inf Model; 2012 Nov; 52(11):3043-52. PubMed ID: 23101941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery and optimization of benzimidazole derivatives as a novel chemotype of farnesoid X receptor (FXR) antagonists.
    Teno N; Iguchi Y; Yamashita Y; Mori N; Une M; Nishimaki-Mogami T; Gohda K
    Bioorg Med Chem; 2017 Mar; 25(6):1787-1794. PubMed ID: 28190654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective nonpeptidic fluorescent ligands for oxytocin receptor: design, synthesis, and application to time-resolved FRET binding assay.
    Karpenko IA; Margathe JF; Rodriguez T; Pflimlin E; Dupuis E; Hibert M; Durroux T; Bonnet D
    J Med Chem; 2015 Mar; 58(5):2547-52. PubMed ID: 25642985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural basis of tropifexor as a potent and selective agonist of farnesoid X receptor.
    Jiang L; Xiao D; Li Y; Dai S; Qu L; Chen X; Guo M; Wei H; Chen Y
    Biochem Biophys Res Commun; 2021 Jan; 534():1047-1052. PubMed ID: 33121679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Farnesoid X receptor agonist reduces serum asymmetric dimethylarginine levels through hepatic dimethylarginine dimethylaminohydrolase-1 gene regulation.
    Hu T; Chouinard M; Cox AL; Sipes P; Marcelo M; Ficorilli J; Li S; Gao H; Ryan TP; Michael MD; Michael LF
    J Biol Chem; 2006 Dec; 281(52):39831-8. PubMed ID: 17065154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.